Thyroid Cancer

Thyroid cancer tests help confirm risk, guide treatment planning, and monitor for recurrence after care. Blood tests cannot diagnose a thyroid nodule by themselves—that requires ultrasound and often a fine-needle aspiration (FNA)biopsy. However, once thyroid cancer is suspected or treated, labs provide essential clues.

For differentiated thyroid cancer (DTC)—papillary and follicular types—clinicians trend thyroglobulin (Tg) and anti-thyroglobulin antibodies (TgAb) as tumor markers after surgery (and radioactive iodine when used). For medullary thyroid carcinoma (MTC)calcitonin and CEA are key markers, and some families need RET genetic testing. Routine thyroid function tests (TSH, Free T4/T3) frame therapy and TSH-suppression goals.
Use these labs to support screening (in select high-risk groups), diagnostic triage, and long-term monitoring—always together with clinician evaluation and imaging when indicated.

Signs, Symptoms & Related Situations

  • Neck & voice: thyroid nodule, neck fullness, hoarseness, trouble swallowing

  • Rapid changes: a nodule that grows quickly, firm or fixed mass, enlarged neck lymph nodes

  • Systemic & specific clues: persistent cough without infection, unexplained weight changes; for MTC—flushing or diarrhea

  • Family & genetic risks: MEN2 syndromes, known RET variants, strong family history of thyroid cancer

  • After treatment: tracking for recurrence with tumor markers and ultrasound

  • Urgent care now: sudden breathing difficulty, stridor, rapidly enlarging neck mass, or severe swallowing problems

All symptoms and risks should be reviewed by a qualified clinician.

Why These Tests Matter

What testing can do

  • Monitor for recurrence with tumor markers (Tg/TgAb for DTC; calcitonin/CEA for MTC)

  • Support staging and follow-up decisions when paired with ultrasound and other imaging

  • Guide therapy goals, including TSH suppression targets in DTC

What testing cannot do

  • Diagnose a thyroid nodule without imaging/biopsy

  • Precisely localize disease—elevated markers prompt imaging and clinician review

  • Overcome assay interferences (e.g., high-dose biotin, TgAb) without proper preparation and method selection

What These Tests Measure (at a glance)

  • Thyroglobulin (Tg): protein made by thyroid cells; a tumor marker after thyroid removal/ablation for DTC. Use the same assay/lab over time.

    • TgAb (anti-thyroglobulin antibodies): can falsely lower Tg in some assays; trending TgAb itself can serve as a surrogate—falling is reassuring, rising may suggest disease.

    • Tg by LC-MS/MS (when available): less affected by antibodies; considered when TgAb positive.

    • TSH-stimulated Tg: measured after rhTSH or temporary hormone withdrawal to improve sensitivity for residual disease (clinician-directed).

  • Calcitonin (MTC): hormone from C-cells; elevated/rising values raise concern for MTC or recurrence.

    • CEA (Carcinoembryonic Antigen): adjunct marker for MTC; trends with disease activity.

    • RET genetic testing: germline testing in MEN2/MTC families or confirmed MTC (clinician-directed).

  • Thyroid function: TSH, Free T4 (± Free T3) to manage TSH suppression in DTC and assess overall thyroid status.

  • Post-operative context: Calcium and PTH may be checked after surgery to evaluate parathyroid function.

  • Important prep: High-dose biotin can distort many immunoassays (TSH, Tg, others). Pause 24–48 hours before testing if advised.

Quick Build Guide

Goal / Scenario Start with Add if needed
New nodule, cancer suspected TSH (function context) Ultrasound/FNA are primary; tumor markers are not diagnostic
Post-thyroidectomy DTC surveillance Tg • TgAb • TSH TSH-stimulated Tg (clinician-directed) • Neck ultrasound
DTC: Rising Tg or TgAb Repeat Tg • TgAb (same assay) Diagnostic imaging (neck US ± RAI scan/CT/PET) per clinician
Medullary thyroid carcinoma Calcitonin • CEA RET genetic testing (family risk) • Imaging per clinician
Pregnancy or planning TSH • Free T4 Coordinate marker timing; avoid RAI; imaging choices are clinician-directed
Post-op symptoms (numbness, tingling) Calcium • PTH Magnesium as directed

How the Testing Process Works

  1. Match tests to your situation: DTC uses Tg/TgAb, MTC uses calcitonin/CEATSH frames therapy.

  2. Prepare for accuracy: pause high-dose biotin if advised; schedule stimulated Tg only under clinician direction.

  3. Provide a sample: standard blood draw for all tumor markers and thyroid function tests.

  4. View secure results: most post within a few days; repeat with the same lab/assay for reliable trends.

  5. Plan next steps: your clinician combines markers with ultrasound and other imaging to confirm or rule out recurrence and to adjust follow-up.

Interpreting Results (General Guidance)

  • After thyroidectomy for DTC

    • Undetectable/very low Tg with negative/stable TgAb → reassuring.

    • Rising Tg (or rising TgAb when TgAb positive) → may suggest persistent/recurrent disease; imaging is usually next.

    • Stimulated Tg that is detectable/ rising vs prior → increases concern; follow clinician plan.

  • In MTC

    • Elevated or rising calcitonin and/or CEA → concern for residual or recurrent disease; trends matter.

  • TSH

    • DTC follow-up often includes TSH suppression; targets are individualized by risk and stage.
      Always interpret results with a qualified healthcare professional. Trends over time and consistent methodsare critical.

Choosing Panels vs. Individual Tests

  • DTC surveillance panel: Tg • TgAb • TSH (± Stimulated Tg when indicated)

  • MTC surveillance panel: Calcitonin • CEA • TSH

  • Function & safety context: Free T4 (± Free T3) to track therapy; Calcium/PTH post-op as needed

  • Genetic risk (clinician-directed): RET testing in MTC/MEN2 families
    Use bundled panels for efficiency, then add targeted markers and stimulated testing only when clinically appropriate.

FAQs

Can a blood test diagnose thyroid cancer?
No. Blood tests cannot diagnose a nodule. Ultrasound and FNA biopsy are the primary tools. Labs help with risk and follow-up.

When is thyroglobulin useful?
After treatment for papillary/follicular cancer. A rising Tg over time can signal recurrence and prompts imaging.

What if I’m positive for anti-Tg antibodies?
TgAb can interfere with some Tg assays. Your clinician may trend TgAb itself and/or use Tg by LC-MS/MS when available.

What does calcitonin show?
It’s a marker for medullary thyroid carcinomaRising calcitonin (and CEA) after treatment increases concern for recurrence.

Why must I use the same lab for Tg?
Different assays can give different numbers. Using the same method allows meaningful trending.

Do I need to stop biotin before testing?
Often yes. High-dose biotin can distort many immunoassays. Ask about a 24–48-hour pause.

How often are these tests repeated?
Cadence depends on risk and stage—often every 6–12 months (more often early on), set by your clinician.

Related Categories & Key Tests

  • Thyroid Tests Hub

  • Thyroid Nodules & Cancer • All Thyroid Tests • Hyperthyroidism & Graves Disease Tests • Hashimoto Thyroiditis Tests • Thyroid Antibodies • Thyroid in Pregnancy

  • Key Tests: Thyroglobulin (Tg) • Anti-Thyroglobulin Antibodies (TgAb) • Tg by LC-MS/MS • TSH-Stimulated Tg • Calcitonin • CEA • TSH • Free T4 • Free T3 • Calcium • PTH • RET Genetic Test

References

  • American Thyroid Association — Management of Thyroid Nodules and Differentiated Thyroid Cancer.
  • American Thyroid Association — Medullary Thyroid Carcinoma Guidelines.
  • NCCN Clinical Practice Guidelines in Oncology — Thyroid Carcinoma.
  • Endocrine Society — Thyroid cancer follow-up and TSH suppression principles.
  • AACE/ACE — Differentiated and Medullary Thyroid Cancer guidance.
  • AACC/NACB — Tumor marker testing (Tg, calcitonin) and immunoassay interference advisories.

Available Tests & Panels

Your Thyroid Cancer Tests menu is pre-populated in the Ulta Lab Tests system. Select a DTC panel (Tg, TgAb, TSH) or an MTC panel (calcitonin, CEA, TSH). Use filters to add Free T4/T3Tg by LC-MS/MS when antibodies are present, and calcium/PTH after surgery. For reliable trending, repeat with the same assay when possible, follow any biotin hold instructions, and review results with your clinician to coordinate imaging and follow-up.

  • Page
  • 1
  • of
  • 1
  • Total Rows
  • 3
Name Matches

The Galectin-3 Test measures levels of galectin-3, a biomarker linked to heart failure, cardiac fibrosis, and inflammation. Elevated results may indicate worsening heart disease, increased risk of hospitalization, or progression of chronic conditions. Doctors use this blood test to assess heart health, guide treatment decisions, and monitor patients with heart failure, offering valuable insight into long-term cardiovascular risk and management.

Blood
Blood Draw

Blood
Blood Draw, Phlebotomist

Blood
Blood Draw, Phlebotomist

When the cells of the thyroid gland begin to multiply at an unregulated rate, the condition is called thyroid cancer. The thyroid gland is shaped like a butterfly and sits below the voice box. As an important component of the endocrine system, the thyroid plays an important role in releasing the hormones that control metabolism.  

The most common indication of these problems comes when an individual or their medical professional notices an unusually large or out of shape thyroid gland. This will usually happen in a physical examination or when the individual is massaging or touching the front of their neck. However, there are a variety of conditions that can result in an abrupt change in the size, texture, or shape of the thyroid gland, and cancer is not necessarily the most common. It will be necessary to perform a full array of medical evaluations to assess the function of the thyroid and delineate the shape of this gland shape will need to be performed as well. 

Other conditions that can also result in an enlarged thyroid include inflammation from Hashimoto Disease and iodine deficiency. 

Sometimes after the thyroid is fully evaluated, the results show the presence of thyroid nodules or tumors. Even still, 90% of these nodules are benign.  

There has been an increase in thyroid diagnosis throughout the modern world, but this is most likely due to improved detection technology rather than an increase in cancer cases. Women are three times as likely to contract this form of cancer as men.  

Thyroid cancer ranks the 8th most common kind of cancer in the US, with an estimated 65,000 new cases being diagnosed each year. The good news is that most of the prognostics are good and even better if they have not spread to other areas of the body, this is true for the two most common types of cancer that we will explore below.  

Types:

There are four major types of thyroid cancer. Each type of cancer attacks a different region of the thyroid, and this can affect prognosis and treatment.

These are the major types of cancer:  

  • Papillary thyroid cancer – 80% of thyroid cancers are papillary cancer making this the most common type of cancer of them all. These cancers do not grow quickly and are not usually fatal.  
  • Follicular thyroid cancer – the second most common type of thyroid cancer accounts for more than 10% of all thyroid cancer cases. This condition is especially common in countries that do not have enough iodine in the diet. Hürthle cell carcinoma accounts for almost 3% of thyroid cancer cases and is a form of follicular thyroid cancer.  
  • Medullary thyroid cancer – accounting for 4% of all thyroid cases, medullary thyroid cancer can appear from nowhere, or the gene can be inherited. When the condition I inherited, it is because of a mutation in the RET gene and typically linked to MEN, or multiple endocrine neoplasia type 2. This type of cancer typically requires a variety of treatments and is not as easy to treat as some of the other forms of thyroid cancer.  
  • Anaplastic thyroid cancer – also known as undifferentiated carcinoma, is the rarest of the common types of thyroid cancer, with only 2% of thyroid cancers falling in this category. It does spread fast and is especially hard to treat.  

Most cases of thyroid cancer can be treated effectively if they are caught early. Even those with follicular or papillary thyroid cancers have a positive prognosis so long as the condition is diagnosed early in its development. According to statistics by the American Cancer Society, 97% of all cases will survive10 years after the initial diagnosis.  

Most thyroid cancers are now found early when they are treatable. Many people with papillary and follicular thyroid cancer have a good prognosis. According to the American Cancer Society, 97% of people with thyroid cancer are alive 10 years after diagnosis. 

Causes

There are not many cases when the specific causes of thyroid cancer are known. But there are some factors, such as age, sex, radiation exposure, and genetic predisposition, that can increase the risk of contracting thyroid cancer.  

In most cases, the specific causes of thyroid cancer are not known. However, there are risk factors associated with age, gender, genetics, and radiation exposure: 

  • Gender – as mentioned, women are two to three times more likely to contract thyroid cancer 
  • Age – 66% of all thyroid cancer cases occur in people between the ages of 22 and 55. 
  • Exposure to Radiation – X-rays, as a part of routine medical examinations, are not considered a factor in thyroid cancer. Nevertheless, there are some types of radiation exposure that can lead to a higher risk of thyroid cancer. This includes radiation treatment performed before the 1960s and those used to treat Hodgkin disease or breast cancer.  
  • Family History – a history of certain conditions in the family can increase the likelihood of developing thyroid cancer. This includes multiple endocrine neoplasia (MEN), medullary thyroid cancer, precancerous colon polyps, and/or goiters. 
  • Genetics – A mutation in the RET gene is the cause of some cases of medullary thyroid cancer. Those with a family history of MTC or multiple endocrine neoplasia (MEN) a blood test will reveal the presence of this mutation.  

Signs and Symptoms

There are a variety of conditions that can have symptoms very similar to those caused by thyroid cancer. For example, the presence of nodules or lumps on the thyroid is common, but they are not usually cancerous. 

Nevertheless, there are yet no screening services available for this type of cancer. This means that it will be up to the individual to work with their medical professional to create a plan to detect this condition early.  

If you notice any of the following warning signs of thyroid cancer, you will want to let your medical practitioner know right away:  

  • A lump on the neck 
  • Neck swelling 
  • Voice changes, including hoarseness 
  • Trouble breathing 
  • Trouble swallowing 
  • Swollen lymph nodes without any respiratory conditions

Laboratory tests 

Screening 

Those who do not have any symptoms of thyroid cancer and have an average risk of developing this condition are not advised to seek out screening tests.  

But those who do have a family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia (MEN 2), may consider getting blood tests to screen for the mutated RET gene,  

Diagnosis and Staging 

If you have shown some of the symptoms of thyroid cancer, your medical practitioner will look for small changes in your thyroid and lymph nodes. They may also ask you about your family history. 

In the end, the only way to arrive at a definite conclusion is through performing a biopsy. But, before you are scheduled for the surgery, your medical examiner will conduct other tests to rule out the possibility that your symptoms are caused by another condition. Other blood tests will help your medical practitioner learn more about the stage and assess the function of the thyroid.  

These blood tests may include: 

Thyroid-stimulating hormone (TSH) – this blood test is used to assess the function of the thyroid. It works to measure the level of TSH released by the pituitary gland. This test is used to ascertain the cause of the symptoms related to thyroid cancer. If the levels of TSH are very high, this could be a symptom of hypothyroidism. A very low level of TSH could be indicative of hyperthyroidism. When the condition is cancer, the levels of TSH are usually normal to high.  

T3 and Free T4 (thyroid hormones) – the levels of these thyroid hormones will also be measured along with the TSH levels. They will be normal in most cases of cancer.  

Calcitonin – this hormone is used by the body to regulate the use of calcium and is formed in the C-cells of the thyroid. The cells that produce this hormone can also turn into medullary thyroid cancer.  This test could be used to diagnose the condition as MTC. The presence of MTC is indicated by higher levels of this hormone.  

RET oncogene – if you have a family history of MTC or your medical practitioner believes you may have this condition, they may suggest DNA testing to find the mutated RET gene. This test is considered the best way to detect MTC.  

Carcinoembryonic antigen (CEA) – levels of this protein are sometimes measured to detect MTC. Those with MTC will typically present higher levels of CEA.  

Biopsy – this method of examination involves removing some of the fluids or tissue from the thyroid itself and examining the sample for evidence of cancer. This is done through fine needle aspiration most of the time. A very thin needle will be inserted into the thyroid gland and guided by an ultrasound to its proper position for extracting a sample. Patients will typically leave the hospital the same day after the procedure and only require a small band-aid to cover the tiny puncture. The samples of tissue or fluids will be examined by a pathologist.  

Molecular testing of biopsied tissue – as much as 30% of biopsies result in an inconclusive report. This can lead to a portion of or the entire thyroid being removed. To avoid this, especially intrusive surgery, new methods of testing are being introduced. Molecular testing can help to determine if thyroid nodules are malignant or not.  

Somatic mutation testing – if the results from examining the biopsied samples are inconclusive, the same tissue can be tested for certain genetic mutations that are associated with cancerous cells. These mutations include BRAF V600E, RET/PTC, PAX8-PPARγ, and RAS. BRAF is especially important in evaluating the likelihood that papillary thyroid cancer will attack again. 

miRNA analysis – miRNAs are small pieces of RNA that can impact the way certain genes behave. Some of these miRNAs are connected to cancerous growths. By detecting their presence in a biopsied tissue sample, they can help to determine if a nodule is malignant or not. Because these miRNAs can also be found in the bloodstream, there is an application for this type of testing in blood samples.